ResearcherJinan UniversityActive in the last 2 years

Lijuan Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5072-390X; OpenAlex author ID A5101428089. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 3

Erianin targets glutathione reductase to trigger immunogenic cell death and sensitize pancreatic cancer to PD-1 blockade. Last author DOI 10.1016/j.canlet.2026.218914 ↗
Erianin inhibits the proliferation and stemness of pancreatic cancer cells by interacting with MEK1/2. Last author DOI 10.1016/j.bcp.2025.117046 ↗
A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer. Co-author DOI 10.1016/j.phymed.2024.155377 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yiqi Zhu · 1 shared paper, 2025 · strength 0.26
- Paper Erianin inhibits the proliferation and stemness of pancreatic cancer cells by interacting with MEK1/2. DOI 10.1016/j.bcp.2025.117046 ↗
Jiaxin Luo · 1 shared paper, 2025 · strength 0.26
- Paper Erianin inhibits the proliferation and stemness of pancreatic cancer cells by interacting with MEK1/2. DOI 10.1016/j.bcp.2025.117046 ↗
Su‐Li Zhu · 1 shared paper, 2024 · strength 0.24
- Paper A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cance… DOI 10.1016/j.phymed.2024.155377 ↗
Xing-Wang Zhou · 1 shared paper, 2024 · strength 0.24
- Paper A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cance… DOI 10.1016/j.phymed.2024.155377 ↗
Caiyun Zhang · 1 shared paper, 2026 · strength 0.23
- Paper Erianin targets glutathione reductase to trigger immunogenic cell death and sensitize pancreatic cancer to PD-1 blockad… DOI 10.1016/j.canlet.2026.218914 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.